Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BIIB091 Formulations in Healthy Participants
NCT06640933Phase 1Completed
- Sponsor
- Biogen
- Start
- Oct 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of biib091 in multiple sclerosis (MS) (6 arms), sponsored by Biogen. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration, Area Under the Concentration-Time Curve From Time Zero to Infinity and 7 more. Started Oct 2024; status: completed.
02
Drugs
biib091
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06640933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640933.